{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:16:03Z","timestamp":1790846163448,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11899-020-00596-z","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T10:55:31Z","timestamp":1597143331000},"page":"409-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib"],"prefix":"10.1007","volume":"15","author":[{"given":"Anand A.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"596_CR1","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W Dameshek","year":"1951","unstructured":"Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372\u20135.","journal-title":"Blood."},{"key":"596_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"596_CR3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic J-P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20138.","journal-title":"Nature"},{"key":"596_CR4","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med"},{"key":"596_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"key":"596_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet."},{"key":"596_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.","journal-title":"PLoS Med"},{"key":"596_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459\u201368.","journal-title":"N Engl J Med"},{"key":"596_CR9","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379\u201390.","journal-title":"N Engl J Med"},{"key":"596_CR10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391\u2013405.","journal-title":"N Engl J Med"},{"key":"596_CR11","doi-asserted-by":"crossref","unstructured":"\u2022 Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129:680\u201392. Comprehensive review detailing Ph-negative MPNs, the molecular features of these diseases, risk stratification, and how to best evaluate for response.","DOI":"10.1182\/blood-2016-10-695957"},{"key":"596_CR12","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115:3109\u201317.","journal-title":"Blood."},{"key":"596_CR13","doi-asserted-by":"crossref","unstructured":"\u2022 Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807. Double-blind RCT establishing ruxolitinib as a treatment strategy compared to placebo in symptomatic, advanced-risk myelofibrosis patients with splenomegaly.","DOI":"10.1056\/NEJMoa1110557"},{"key":"596_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3324\/haematol.2014.115840","volume":"100","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100:479\u201388.","journal-title":"Haematologica"},{"key":"596_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10:55.","journal-title":"J Hematol Oncol"},{"key":"596_CR16","doi-asserted-by":"crossref","unstructured":"\u2022 Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398. RCT establishing ruxolitinib as a treatment strategy compared to best available therapy in symptomatic, advanced-risk myelofibrosis patients with splenomegaly.","DOI":"10.1056\/NEJMoa1110556"},{"key":"596_CR17","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian J-J, Al-Ali HK, Gisslinger H, Knoops L, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30:1701\u20137.","journal-title":"Leukemia"},{"key":"596_CR18","doi-asserted-by":"crossref","unstructured":"\u2022 Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426\u201335. RCT establishing ruxolitinib as a treatment strategy compared to standard therapy in polycythemia vera patients with an inadequate response to hydroxyurea.","DOI":"10.1056\/NEJMoa1409002"},{"key":"596_CR19","doi-asserted-by":"publisher","unstructured":"Kiladjian J-J, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020; Available from: https:\/\/doi.org\/10.1016\/S2352-3026(19)30207-8.","DOI":"10.1016\/S2352-3026(19)30207-8"},{"key":"596_CR20","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","volume":"119","author":"A Eghtedar","year":"2012","unstructured":"Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012;119:4614\u20138.","journal-title":"Blood"},{"key":"596_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.clml.2014.08.003","volume":"15","author":"N Pemmaraju","year":"2015","unstructured":"Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, et al. A phase I\/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15:171\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"596_CR22","doi-asserted-by":"crossref","unstructured":"\u2022 Odenike O. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2018;132:2339\u201350. Comprehensive review of treatment strategies in myeloproliferative neoplasms that have progressed to blast phase.","DOI":"10.1182\/blood-2018-03-785907"},{"key":"596_CR23","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1:643\u201351. RCT demonstrating the efficacy of fedratinib in symptomatic, advanced-risk, JAK-inhibitor naive myelofibrosis patients with compared to placebo.","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"596_CR24","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Harrison CN, Schaap N, Vannucchi AM, Kiladjian J-J, Tiu RV, Zachee P, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4:e317\u201324. Single-arm open-label trial demonstrating efficacy of fedratinib in symptomatic, advanced-risk, myelofibrosis patients that had previously received ruxolitinib.","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"596_CR25","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Mesa RA, Kiladjian J-J, Catalano JV, Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis. J Clin Oncol. 2017;35:3844\u201350. RCT demonstrating non-inferiority of momelotinib when compared to ruxolitinib in symptomatic, advanced-risk, myelofibrosis patients.","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"596_CR26","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5:e73\u201381. RCT demonstrating that momelotinib was not superior to best available therapy in symptomatic, advanced-risk, myelofibrosis patients that had previously received ruxolitinib.","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"596_CR27","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4:e225\u201336. RCT demonstrating superiority of pacritinib compared to best available therapy excluding JAK inhibition in symptomatic, advanced-risk, JAK-inhibitor naive myelofibrosis irrespective of baseline cytopenias.","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"596_CR28","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4:652\u20139. RCT demonstrating superiorty of pacritinib compared to best available therapy including ruxolitinib in symptomatic, advanced-risk, myelofibrosis with thrombocytopenia.","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"596_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29:789\u201396.","journal-title":"J Clin Oncol"},{"key":"596_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12967-015-0644-4","volume":"13","author":"C Jamieson","year":"2015","unstructured":"Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, et al. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med. 2015;13:294.","journal-title":"J Transl Med"},{"key":"596_CR31","unstructured":"\u2022 Harrison CN, Mesa RA, Jamieson C, Hood J, Bykowski J, Zuccoli G, et al. Case series of potential Wernicke\u2019s encephalopathy in patients treated with fedratinib. Blood. Am Soc Hematol. 2017;130:4197\u20137. Case series establishing that the risk of Wernicke's encephalopathy with fedratinib was quite low."},{"key":"596_CR32","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1124\/dmd.114.058883","volume":"42","author":"Q Zhang","year":"2014","unstructured":"Zhang Q, Zhang Y, Diamond S, Boer J, Harris JJ, Li Y, et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke\u2019s encephalopathy. Drug Metab Dispos. 2014;42:1656\u201362.","journal-title":"Drug Metab Dispos"},{"key":"596_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.neulet.2017.01.041","volume":"642","author":"AS Hazell","year":"2017","unstructured":"Hazell AS, Afadlal S, Cheresh DA, Azar A. Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke\u2019s encephalopathy. Neurosci Lett. 2017;642:163\u20137.","journal-title":"Neurosci Lett"},{"key":"596_CR34","unstructured":"Hood J, Hazell A. Fedratinib does not inhibit thiamine uptake or induce experimental Wernicke\u2019s encephalopathy in nonclinical studies. Blood Am Soc Hematol. 2017;130:4993\u20133."},{"key":"596_CR35","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s40265-019-01205-x","volume":"79","author":"HA Blair","year":"2019","unstructured":"Blair HA. Fedratinib: first approval. Drugs Springer. 2019;79:1719\u201325.","journal-title":"Drugs"},{"key":"596_CR36","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, et al. International working group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT). Blood. 2006;108:1497\u2013503.","journal-title":"Blood."},{"key":"596_CR37","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/leu.2013.71","volume":"27","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27:1322\u20137.","journal-title":"Leukemia."},{"key":"596_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.13262","volume":"169","author":"RA Abdelrahman","year":"2015","unstructured":"Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Pardanani A, et al. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol. 2015;169:77\u201380.","journal-title":"Br J Haematol"},{"key":"596_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3324\/haematol.2016.148924","volume":"102","author":"V Gupta","year":"2017","unstructured":"Gupta V, Mesa RA, Deininger MWN, Rivera CE, Sirhan S, Brachmann CB, et al. A phase 1\/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica. 2017;102:94\u2013102.","journal-title":"Haematologica."},{"key":"596_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-016-0367-x","volume":"9","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, Deeg HJ. Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016;9:137.","journal-title":"J Hematol Oncol"},{"key":"596_CR41","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1182\/blood-2013-02-484832","volume":"125","author":"RS Komrokji","year":"2015","unstructured":"Komrokji RS, Seymour JF, Roberts AW, Wadleigh M, To LB, Scherber R, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2\/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015;125:2649\u201355.","journal-title":"Blood."},{"key":"596_CR42","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian J-J, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098\u2013103.","journal-title":"J Clin Oncol"},{"key":"596_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","volume":"118","author":"R Scherber","year":"2011","unstructured":"Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401\u20138.","journal-title":"Blood."},{"key":"596_CR44","doi-asserted-by":"crossref","unstructured":"\u2022 Leroy E, Constantinescu SN. Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition. Leukemia. 2017;31:1023\u201338. Comprehensive review detailing novel strategies of JAK inhibition.","DOI":"10.1038\/leu.2017.43"},{"key":"596_CR45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature11303","volume":"489","author":"P Koppikar","year":"2012","unstructured":"Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012;489:155\u20139.","journal-title":"Nature."},{"key":"596_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","volume":"28","author":"SC Meyer","year":"2015","unstructured":"Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, et al. CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms. Cancer Cell. 2015;28:15\u201328.","journal-title":"Cancer Cell"},{"key":"596_CR47","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/leu.2011.255","volume":"26","author":"A Deshpande","year":"2012","unstructured":"Deshpande A, Reddy MM, Schade GOM, Ray A, Chowdary TK, Griffin JD, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia. 2012;26:708\u201315.","journal-title":"Leukemia."},{"key":"596_CR48","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"RL Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673\u201383.","journal-title":"Nat Rev Cancer"},{"key":"596_CR49","doi-asserted-by":"publisher","first-page":"ra122","DOI":"10.1126\/scisignal.2005301","volume":"7","author":"PS Winter","year":"2014","unstructured":"Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, et al. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Sci Signal. 2014;7:ra122.","journal-title":"Sci Signal"},{"key":"596_CR50","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1038\/leu.2013.167","volume":"27","author":"I Khan","year":"2013","unstructured":"Khan I, Huang Z, Wen Q, Stankiewicz MJ, Gilles L, Goldenson B, et al. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia. 2013;27:1882\u201390.","journal-title":"Leukemia."},{"key":"596_CR51","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1172\/JCI98785","volume":"130","author":"S Stivala","year":"2019","unstructured":"Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, et al. Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019;130:1596\u2013611.","journal-title":"J Clin Invest"},{"key":"596_CR52","doi-asserted-by":"publisher","unstructured":"Patel AA, Cahill K, Charnot-Katsikas A, Liu H, Gurbuxani S, Thirman M, et al. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020; Available from:. https:\/\/doi.org\/10.1111\/bjh.16709.","DOI":"10.1111\/bjh.16709"},{"key":"596_CR53","doi-asserted-by":"crossref","unstructured":"\u2022 Pettit K, Odenike O. Novel therapies for myelofibrosis. Curr Hematol Malig Rep. 2017;12:611\u201324. Comprehensive review of novel therapies in myelofibrosis moving beyond JAK inhibition.","DOI":"10.1007\/s11899-017-0403-0"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00596-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-020-00596-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00596-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T15:51:16Z","timestamp":1696521076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-020-00596-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["596"],"URL":"https:\/\/doi.org\/10.1007\/s11899-020-00596-z","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,11]]},"assertion":[{"value":"11 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Patel has none to report.Dr. Odenike has the following to report: Consulting or advisory role with Abbvie, Impact Biomedicines, Celgene, Novartis. Research funding from Celgene, Incyte, Astex Pharmaceuticals, NS Pharma, Abbvie, Janssen Oncology, Oncotherapy, Agios, AstraZeneca, CTI BioPharm Corp, Kartos.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects perfomed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}